A look at the shareholders of Gan & Lee Pharmaceuticals. (SHSE:603087) can tell us which group is most powerful. And the group that holds the biggest piece of the pie are individual insiders with 33% ownership. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn).
And last week, insiders endured the biggest losses as the stock fell by 4.3%.
Let's take a closer look to see what the different types of shareholders can tell us about Gan & Lee Pharmaceuticals.
See our latest analysis for Gan & Lee Pharmaceuticals
SHSE:603087 Ownership Breakdown November 23rd 2022
What Does The Institutional Ownership Tell Us About Gan & Lee Pharmaceuticals?
Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.
As you can see, institutional investors have a fair amount of stake in Gan & Lee Pharmaceuticals. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at Gan & Lee Pharmaceuticals' earnings history below. Of course, the future is what really matters.
SHSE:603087 Earnings and Revenue Growth November 23rd 2022
Hedge funds don't have many shares in Gan & Lee Pharmaceuticals. From our data, we infer that the largest shareholder is Gan Zhongru (who also holds the title of Top Key Executive) with 33% of shares outstanding. Its usually considered a good sign when insiders own a significant number of shares in the company, and in this case, we're glad to see a company insider play the role of a key stakeholder. Meanwhile, the second and third largest shareholders, hold 12% and 8.5%, of the shares outstanding, respectively.
After doing some more digging, we found that the top 3 shareholders collectively control more than half of the company's shares, implying that they have considerable power to influence the company's decisions.
While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. While there is some analyst coverage, the company is probably not widely covered. So it could gain more attention, down the track.
Insider Ownership Of Gan & Lee Pharmaceuticals
The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO.
I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions.
Our information suggests that insiders maintain a significant holding in Gan & Lee Pharmaceuticals.. It has a market capitalization of just CN¥20b, and insiders have CN¥6.6b worth of shares in their own names. That's quite significant. Most would be pleased to see the board is investing alongside them. You may wish to access this free chart showing recent trading by insiders.
General Public Ownership
The general public, who are usually individual investors, hold a 26% stake in Gan & Lee Pharmaceuticals. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders.
Private Company Ownership
It seems that Private Companies own 28%, of the Gan & Lee Pharmaceuticals stock. Private companies may be related parties. Sometimes insiders have an interest in a public company through a holding in a private company, rather than in their own capacity as an individual. While it's hard to draw any broad stroke conclusions, it is worth noting as an area for further research.
Public Company Ownership
It appears to us that public companies own 3.5% of Gan & Lee Pharmaceuticals. We can't be certain but it is quite possible this is a strategic stake. The businesses may be similar, or work together.
Next Steps:
While it is well worth considering the different groups that own a company, there are other factors that are even more important. Be aware that Gan & Lee Pharmaceuticals is showing 3 warning signs in our investment analysis , and 1 of those doesn't sit too well with us...
But ultimately it is the future, not the past, that will determine how well the owners of this business will do. Therefore we think it advisable to take a look at this free report showing whether analysts are predicting a brighter future.
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
看一看甘利製藥的股東。(上海證券交易所:603087)可以告訴我們哪一組最強大。而持有這塊蛋糕最大份額的是擁有33%股權的個人內部人士。也就是説,如果股價上漲,該集團將受益最大(如果股價下跌,該集團將損失最大)。
上週,內部人士遭受了最大的損失,股價下跌了4.3%。
讓我們仔細看看不同類型的股東能告訴我們關於甘利製藥的什麼。
查看我們對甘利製藥的最新分析
上海證交所:603087所有權明細2022年11月23日
關於甘利製藥,機構持股告訴了我們什麼?
機構通常在向自己的投資者報告時,以基準來衡量自己,因此一旦一隻股票被納入主要指數,它們往往會對這隻股票變得更加熱情。我們預計,大多數公司都會有一些機構登記在冊,特別是在它們正在增長的情況下。
正如你所看到的,機構投資者在甘利製藥公司擁有相當數量的股份。這可以表明該公司在投資界具有一定的公信力。然而,最好警惕依賴機構投資者帶來的所謂驗證。他們也一樣,有時也會犯錯。如果多家機構同時改變對一隻股票的看法,你可能會看到股價迅速下跌。因此,值得一看的是下面甘利製藥的盈利歷史。當然,未來才是真正重要的。
上海證交所:603087收益和收入增長2022年11月23日
對衝基金在Gan&Lee PharmPharmticals的股份並不多。根據我們的數據,我們推測最大的股東是甘忠儒(他也擁有最高管理層的頭銜),持有33%的流通股。當內部人持有公司大量股份時,這通常被認為是一個好兆頭,在這種情況下,我們很高興看到公司內部人播放扮演關鍵利益相關者的角色。與此同時,第二大和第三大股東分別持有流通股的12%和8.5%。
經過進一步挖掘,我們發現,前3名股東合計控制了公司一半以上的股份,這意味着他們擁有相當大的權力來影響公司的決策。
雖然研究一家公司的機構所有權數據是有意義的,但研究分析師的情緒以瞭解風向也是有意義的。雖然有一些分析師的報道,但該公司可能沒有得到廣泛的報道。因此,它可以獲得更多的關注,在賽道上。
甘利製藥的內部人所有權
公司內部人的定義可能是主觀的,而且在不同的司法管轄區之間確實有所不同。我們的數據反映了個別內部人士,至少捕捉到了董事會成員。管理層最終要向董事會負責。然而,經理人擔任執行董事會成員並不少見,尤其是如果他們是創始人或首席執行官的話。
我通常認為內部人持股是一件好事。然而,在某些情況下,這會讓其他股東更難讓董事會對決策負責。
我們的信息顯示,內部人士持有甘利製藥的大量股份。它的市值僅為人民幣200億元,內部人士以自己的名義持有價值人民幣66億元的股票。這是非常重要的。大多數人會高興地看到董事會與他們一起投資。你可能希望訪問這張顯示內部人士最近交易的免費圖表。
一般公有制
公眾通常是個人投資者,他們持有甘利製藥26%的股份。這種規模的所有權雖然可觀,但如果決策與其他大股東不同步,可能不足以改變公司政策。
私營公司所有權
看起來私營公司擁有28%的Gan&Lee製藥股份。私營公司可能是關聯方。有時,內部人士通過持有一傢俬人公司來對上市公司感興趣,而不是以個人身份。雖然很難得出任何大致的中風結論,但值得注意的是,這是一個值得進一步研究的領域。
上市公司所有權
在我們看來,上市公司擁有Gan&Lee製藥公司3.5%的股份。我們不能確定,但很有可能這是一個戰略利益攸關方。這些業務可能是相似的,也可能是合作的。
接下來的步驟:
雖然考慮擁有一家公司的不同集團是很值得的,但還有其他更重要的因素。請注意,甘利製藥公司正在展示我們的投資分析中的3個警告信號,其中一條不太適合我們……
但最終這就是未來,而不是過去,這將決定這家企業的所有者將做得多好。因此,我們認為,看看這份免費報告是明智的,它顯示了分析師是否預測到了更光明的未來。
注:本文中的數字是使用過去12個月的數據計算的,指的是截至財務報表日期的最後一個月的12個月期間。這可能與全年的年度報告數字不一致。
對這篇文章有什麼反饋嗎?擔心內容嗎? 保持聯繫直接與我們聯繫。或者,也可以給編輯組發電子郵件,地址是implywallst.com。
本文由Simply Wall St.撰寫,具有概括性。我們僅使用不偏不倚的方法提供基於歷史數據和分析師預測的評論,我們的文章並不打算作為財務建議。它不構成買賣任何股票的建議,也沒有考慮你的目標或你的財務狀況。我們的目標是為您帶來由基本面數據驅動的長期重點分析。請注意,我們的分析可能不會將最新的對價格敏感的公司公告或定性材料考慮在內。Simply Wall St.對上述任何一隻股票都沒有持倉。